357 related articles for article (PubMed ID: 18243843)
1. A report on the implementation aspects of the International Atomic Energy Agency's first doctoral coordinated research project, "Management of liver cancer using radionuclide methods with special emphasis on trans-arterial radio-conjugate therapy and internal dosimetry".
Padhy AK; Dondi M
Semin Nucl Med; 2008 Mar; 38(2):S5-12. PubMed ID: 18243843
[TBL] [Abstract][Full Text] [Related]
2. Use of the Oak Ridge National Laboratory tungsten-188/rhenium-188 generator for preparation of the rhenium-188 HDD/lipiodol complex for trans-arterial liver cancer therapy.
Jeong JM; Knapp FF
Semin Nucl Med; 2008 Mar; 38(2):S19-29. PubMed ID: 18243839
[TBL] [Abstract][Full Text] [Related]
3. Thematic planning: the role of the International Atomic Energy Agency in promoting education, medical research, and technology transfer among nuclear medicine communities of developing countries.
Padhy AK; Dondi M
Semin Nucl Med; 2008 Mar; 38(2):S2-4. PubMed ID: 18243840
[TBL] [Abstract][Full Text] [Related]
4. International Atomic Energy Agency-sponsored multination study of intra-arterial rhenium-188-labeled lipiodol in the treatment of inoperable hepatocellular carcinoma: results with special emphasis on prognostic value of dosimetric study.
Bernal P; Raoul JL; Stare J; Sereegotov E; Sundram FX; Kumar A; Jeong JM; Pusuwan P; Divgi C; Zanzonico P; Vidmar G; Buscombe J; Chau TT; Saw MM; Chen S; Ogbac R; Dondi M; Padhy AK
Semin Nucl Med; 2008 Mar; 38(2):S40-5. PubMed ID: 18243842
[TBL] [Abstract][Full Text] [Related]
5. Patient-specific radiation dosimetry for radionuclide therapy of liver tumors with intrahepatic artery rhenium-188 lipiodol.
Zanzonico PB; Divgi C
Semin Nucl Med; 2008 Mar; 38(2):S30-9. PubMed ID: 18243841
[TBL] [Abstract][Full Text] [Related]
6. Availability of rhenium-188 from the alumina-based tungsten-188/rhenium-188 generator for preparation of rhenium-188-labeled radiopharmaceuticals for cancer treatment.
Knapp FF; Beets AL; Guhlke S; Zamora PO; Bender H; Palmedo H; Biersack HJ
Anticancer Res; 1997; 17(3B):1783-95. PubMed ID: 9179235
[TBL] [Abstract][Full Text] [Related]
7. Rhenium-188: availability from the (188)W/(188)Re generator and status of current applications.
Pillai MR; Dash A; Knapp FF
Curr Radiopharm; 2012 Jul; 5(3):228-43. PubMed ID: 22642385
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and dosimetry of 188 Re-pharmaceuticals.
Ferro-Flores G; Arteaga de Murphy C
Adv Drug Deliv Rev; 2008 Sep; 60(12):1389-401. PubMed ID: 18547675
[TBL] [Abstract][Full Text] [Related]
9. Intra-arterial rhenium-188 lipiodol in the treatment of inoperable hepatocellular carcinoma: results of an IAEA-sponsored multination study.
Bernal P; Raoul JL; Vidmar G; Sereegotov E; Sundram FX; Kumar A; Jeong JM; Pusuwan P; Divgi C; Zanzonico P; Stare J; Buscombe J; Minh CT; Saw MM; Chen S; Ogbac R; Padhy AK
Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1448-55. PubMed ID: 17692473
[TBL] [Abstract][Full Text] [Related]
10. Lipiodol solution of 188Re-HDD as a new therapeutic agent for transhepatic arterial embolization in liver cancer: preclinical study in a rabbit liver cancer model.
Paeng JC; Jeong JM; Yoon CJ; Lee YS; Suh YG; Chung JW; Park JH; Chung JK; Son M; Lee MC
J Nucl Med; 2003 Dec; 44(12):2033-8. PubMed ID: 14660730
[TBL] [Abstract][Full Text] [Related]
11. Management of postsurgical recurrence of hepatocellular carcinoma with rhenium 188-HDD labeled iodized oil.
Kumar A; Srivastava DN; Bal C
J Vasc Interv Radiol; 2006 Jan; 17(1):157-61. PubMed ID: 16415146
[TBL] [Abstract][Full Text] [Related]
12. Preparation and biodistribution of rhenium-188 ECD/Lipiodol in rats following hepatic arterial injection.
Luo TY; Hsieh BT; Wang SJ; Lin WY; Lee TW; Shen LH; Su MJ
Nucl Med Biol; 2004 Jul; 31(5):671-7. PubMed ID: 15219287
[TBL] [Abstract][Full Text] [Related]
13. Biologic dosimetry of 188Re-HDD/lipiodol versus 131I-lipiodol therapy in patients with hepatocellular carcinoma.
De Ruyck K; Lambert B; Bacher K; Gemmel F; De Vos F; Vral A; de Ridder L; Dierckx RA; Thierens H
J Nucl Med; 2004 Apr; 45(4):612-8. PubMed ID: 15073257
[TBL] [Abstract][Full Text] [Related]
14. Radionuclide therapy for hepatocellular carcinoma: indication, cost and efficacy.
Bal CS; Kumar A
Trop Gastroenterol; 2008; 29(2):62-70. PubMed ID: 18972764
[TBL] [Abstract][Full Text] [Related]
15. Feasibility of high activity rhenium-188-microsphere in hepatic radioembolization.
Liepe K; Brogsitter C; Leonhard J; Wunderlich G; Hliscs R; Pinkert J; Folprecht G; Kotzerke J
Jpn J Clin Oncol; 2007 Dec; 37(12):942-50. PubMed ID: 18094017
[TBL] [Abstract][Full Text] [Related]
16. Rhenium-188 based radiopharmaceuticals for treatment of liver tumours.
Lambert B; Bacher K; Defreyne L
Q J Nucl Med Mol Imaging; 2009 Jun; 53(3):305-10. PubMed ID: 19521309
[TBL] [Abstract][Full Text] [Related]
17. 131-iodine Lipiodol therapy in hepatocellular carcinoma.
Raoul JL; Boucher E; Roland V; Garin E
Q J Nucl Med Mol Imaging; 2009 Jun; 53(3):348-55. PubMed ID: 19521315
[TBL] [Abstract][Full Text] [Related]
18. Strengthening radiopharmacy practice in IAEA Member States.
Duatti A; Bhonsle U
Semin Nucl Med; 2013 May; 43(3):188-94. PubMed ID: 23561456
[TBL] [Abstract][Full Text] [Related]
19. 188Re-HDD/lipiodol therapy for hepatocellular carcinoma: a phase I clinical trial.
Lambert B; Bacher K; Defreyne L; Gemmel F; Van Vlierberghe H; Jeong JM; Dierckx RA; Van de Wiele C; Thierens H; De Vos F
J Nucl Med; 2005 Jan; 46(1):60-6. PubMed ID: 15632035
[TBL] [Abstract][Full Text] [Related]
20. IAEA support to medical physics in nuclear medicine.
Meghzifene A; Sgouros G
Semin Nucl Med; 2013 May; 43(3):181-7. PubMed ID: 23561455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
